References
- Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
- Gordon L I, Harrington D, Andersen J, Colgan J, Glick J, Neimann R, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342–1349
- Cooper I A, Wolf M M, Robertson T I, Fox R M, Matthews J P, Stone J M, , The Australian and New Zealand Lymphoma Group, et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 769–778
- The International Non-Hodgkin's Lymphoma Prognostic Factors project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
- Gianni A M, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297
- Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479
- Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli M R, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomised trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796–2802
- Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
- Engelhard M, Meusers P, Kingreen D, Siegert W, Engert A, Diehl V, et al. Intensive chemotherapy for high-risk patients with high-grade malignant non-Hodgkin lymphomas: a pilot study using adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide, and dexamethasone (ACOMED Protocol). Onkologie 1994; 17: 72–76
- Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030
- Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003; 14: 881–893
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
- Habermann T M, Weller E A, Morrison V A, Cassileth P A, Cohn J B, Dakhil S R, et al. Phase III Trial of Rituximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 102, Abstr #8